Nelli, F.; Ruggeri, E.M.; Schirripa, M.; Virtuoso, A.; Giannarelli, D.; Raso, A.; Remotti, D.; Fabbri, A.
Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring Agency. Curr. Oncol. 2024, 31, 7647-7662.
https://doi.org/10.3390/curroncol31120564
AMA Style
Nelli F, Ruggeri EM, Schirripa M, Virtuoso A, Giannarelli D, Raso A, Remotti D, Fabbri A.
Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring Agency. Current Oncology. 2024; 31(12):7647-7662.
https://doi.org/10.3390/curroncol31120564
Chicago/Turabian Style
Nelli, Fabrizio, Enzo Maria Ruggeri, Marta Schirripa, Antonella Virtuoso, Diana Giannarelli, Armando Raso, Daniele Remotti, and Agnese Fabbri.
2024. "Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring Agency" Current Oncology 31, no. 12: 7647-7662.
https://doi.org/10.3390/curroncol31120564
APA Style
Nelli, F., Ruggeri, E. M., Schirripa, M., Virtuoso, A., Giannarelli, D., Raso, A., Remotti, D., & Fabbri, A.
(2024). Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring Agency. Current Oncology, 31(12), 7647-7662.
https://doi.org/10.3390/curroncol31120564
